Oppenheimer analyst Jay Olson lowered the price target on Neurocrine Bio. (NASDAQ: NBIX) to $150.00 (from $154.00) while maintaining an ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Analyst PT Change

Neurocrine Bio. (NBIX) PT Raised to $74 at BMO CapitalFebruary 14, 2022 7:03 AM UPDATE: Neurocrine Bio. (NBIX) PT Lowered to $95 at Mizuho SecuritiesFebruary 14, 2022 6:54 AM Neurocrine Bio. (NBIX) PT Raised to $92 at RBC CapitalFebruary 14, 2022 6:38 AM Needham & Company Reiterates Neurocrine (NBIX) at Hold, "Love Execution on Ingrezza" but Cautious on Future Pipeline ReadoutsFebruary 14, 2022 5:51 AM Form 10-K NEUROCRINE BIOSCIENCES For: Dec 31February 11, 2022 5:21 PM Neurocrine (NBIX) Maintained at Underperform by BMO, PT Hiked to $74, Analyst Sees Challenging Q1February 11, 2022 4:41 PM Raymond James Reiterates Outperform Rating on Neurocrine Bio. (NBIX), Company is Well Positioned to Execute as COVID DissipatesFebruary 11, 2022 11:44 AM Neurocrine Bio. (NBIX) PT Lowered to $136 at Stifel, Ingrezza's Growth and Sales, and Pipeline Prospects Remain Key Focus for Investors, February 11, 2022 10:09 AM Needham & Company Reiterates Hold on Neurocrine (NBIX), Calls Earnings Uneventful, Does Not Expect Big Move in StockFebruary 11, 2022 8:19 AM BMO Capital Reiterates Neurocrine (NBIX) at Outperform, But Notes Post-Pandemic Headwinds to Achieving GuidanceFebruary 11, 2022 8:09 AM Neurocrine Biosciences (NBIX) Misses Q4 EPS by 54cFebruary 11, 2022 7:32 AM Form 8-K NEUROCRINE BIOSCIENCES For: Feb 11February 11, 2022 7:32 AM Neurocrine Biosciences Reports Fourth Quarter and Fiscal 2021 Financial Results and Provides Financial Expectations for Fiscal 2022February 11, 2022 7:30 AM